Semaglutide is proven to lead to medullary thyroid mobile carcinoma in rodents. When its scientific relevance to people is not known, the FDA advises never to administer this drug in People with a private or family heritage of medullary thyroid carcinoma. Semaglutide also poses a possibility of pancreatitis and dehydration. https://semaglutide87542.59bloggers.com/31028944/a-review-of-tirzepatide